The importance of patient-reported outcomes in clinical trials and strategies for future optimization
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
Patient-reported outcomes (PROs) can be included in clinical trials as primary or secondary endpoints and are increasingly recognized by regulators, clinicians, and patients as valuable tools to collect patient-centered data. PROs provide unique information on the impact of a medical condition and its treatment from the patient's perspective; therefore, PROs can be included in clinical trials to ensure the impact of a trial intervention is comprehensively assessed. This review first discusses examples of how PRO endpoints have added value to clinical trial interpretation. Second, it describes the problems with current practices in designing, implementing, and reporting PRO studies, and how these problems may be addressed by complying with guidance for protocol development, selecting appropriate PRO measures to match clinically motivated PRO hypotheses, minimizing the rates of avoidable missing PRO data, analyzing and interpreting PRO data, and transparently reporting PRO findings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The weaRAble-PRO study administered a selection of validated PRO measures for RA in complement to bespoke digital PRO assessments—that are validated in clinical trials”
From Digital health technologies and machine learning augment patient reported outcomes to remotely characterise rheumatoid arthritis (2024) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
the CONSORT Group, Schulz, K. F., Altman, D. G., & Moher, D. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-18 · Cited by 13,371
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
Schulz, K. F., Altman, D. G., Moher, D., & for the CONSORT Group (2010) · BMJ · doi:10.1136/bmj.c332 · Cited by 9,329
SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials
Chan, A.-W., Tetzlaff, J. M., Altman, D. G., Laupacis, A., Gøtzsche, P. C., Krleža-Jerić, K., Hróbjartsson, A., Mann, H., Dickersin, K., Berlin, J. A., et al. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-3-201302050-00583 · Cited by 7,363 · cited 2×
“It should be used in conjunction with the SPIRIT 2013 statement 32,33 when developing a research protocol for a trial with a primary or important secondary PRO endpoint.”
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
Chan, A.-W., Tetzlaff, J. M., Gotzsche, P. C., Altman, D. G., Mann, H., Berlin, J. A., Dickersin, K., Hrobjartsson, A., Schulz, K. F., Parulekar, W. R., et al. (2013) · BMJ · doi:10.1136/bmj.e7586 · Cited by 6,251 · cited 2×
“It should be used in conjunction with the SPIRIT 2013 statement 32,33 when developing a research protocol for a trial with a primary or important secondary PRO endpoint.”
CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials
Schulz, K. F., Altman, D. G., Moher, D., & for the CONSORT Group (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000251 · Cited by 2,296
Tannock, I. F., Osoba, D., Stockler, M. R., Ernst, D. S., Neville, A. J., Moore, M. J., Armitage, G. R., Wilson, J. J., Venner, P. M., Coppin, C. M., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.6.1756 · Cited by 1,580 · cited 2×
“21,22 The PRO endpoints led to regulatory approval of mitoxantrone for this indication and wide implementation in the clinic.”
InfluentialSelf-citationReporting of Patient-Reported Outcomes in Randomized Trials: The CONSORT PRO Extension
Calvert, M., Blazeby, J., Altman, D. G., Revicki, D. A., Moher, D., Brundage, M. D., & CONSORT PRO Group, F. T. (2013) · JAMA · doi:10.1001/jama.2013.879 · Cited by 1,386 · cited 2×
“This work informed the development of a CONSORT-PRO Extension (Consolidated Standards of Reporting Trials), which can be considered the minimum reporting items for PRO endpoints (primary or key secondary) in RCTs. 73 CONSORT-PRO consists of 14 items, five of which were newly developed PRO-specific reporting recommenda…”
Self-citationReducing waste from incomplete or unusable reports of biomedical research
Glasziou, P., Altman, D. G., Bossuyt, P., Boutron, I., Clarke, M., Julious, S., Michie, S., Moher, D., & Wager, E. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62228-x · Cited by 1,319 · cited 1×
“However, the issue of non-reporting of PROs is emerging and requires attention, as it is unethical to waste the funding, resources, and patients’ efforts expended in PRO data collection.(71)”
Cherny, N. I., Sullivan, R., Dafni, U., Kerst, J. M., Sobrero, A., Zielinski, C., de Vries, E. G. E., & Piccart, M. J. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv249 · Cited by 818 · cited 2×
“In oncology, for example, the American Society of Clinical Oncology (ASCO)(10) and European Society for Medical Oncology (ESMO)(11) have proposed standardized approaches to evaluate clinical trial results by using scores to evaluate the Magnitude of Clinical Benefit (ESMO MCB) or the Net Health Benefit (ASCO), which i…”
Calvert, M., Kyte, D., Mercieca-Bebber, R., Slade, A., Chan, A.-W., King, M. T., and the SPIRIT-PRO Group, Hunn, A., Bottomley, A., Regnault, A., et al. (2018) · JAMA · doi:10.1001/jama.2017.21903 · Cited by 814 · cited 5×
“A second review examined the PRO content of 26 protocols of Phase III international, ovarian cancer trials published between 2000 and 2016 against a list of PRO-specific items that would eventually inform the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT)-PRO Extension.(29,30) Of the 26 tr…”
InfluentialSelf-citation
Research works printed but not linked: 2
- [15]Food and Drug Administration Ovarian Cancer Endpoints Workshop April 26, 2006, Meeting Summary 2006 Available from: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/Developmen-tResources/CancerDrugs/ucm094598.pdf accessed 09 August 2016 https://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/ucm120657.pdf Accessed 14 August 2017.v
- [56]Mercieca-Bebber R Palmer MJ Brundage M Design, implementation and reporting strategies to reduce the instance and impact of missing patient-reported outcome (PRO) data: a systematic review BMJ Open 2016 6 6 e010938 PMC4916640 27311907
Cited by
Items 601–660 of 660
Majercak, K. R., Perfetto, E. M., & Villalonga-Olives, E. (2022) · Figshare · doi:10.6084/m9.figshare.18864994
La médecine périopératoire : les perspectives
Capdevila, M., Gall, A. L., Rontes, O., Gonnu-Levallois, S., James, A., Abrard, S., Vardon, F., Salaün, J., Bouaoud, J., Heyer, L., et al. (2025) · Anesthésie & Réanimation · doi:10.1016/j.anrea.2025.10.013 · Cited by 1
Preoperative opioid use negatively impacts pain and met expectations 2 years after hip arthroscopy
Vellala, S., Healey, K., McCurdy, M. A., Ventimiglia, D. J., Blommer, J. M., Henn, R. F., & Meredith, S. J. (2025) · Journal of Orthopaedics · doi:10.1016/j.jor.2025.12.036
Mukowski-Kickhöfel, R., Otto, L. R., & Rogge, A. A. (2026) · Patient Preference and Adherence · doi:10.2147/ppa.s563659
Rawlings, G. H., Whitaker, L., Gaskell, C. J., & Reuber, M. (2026) · Seizure · doi:10.1016/j.seizure.2025.12.015
Die Messung von „Patient-reported Outcomes“ als Instrument patientenzentrierter Versorgung?
Rose, M. (2026) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-026-04187-w
Development of a core outcome set for traditional Chinese dietotherapy in type 2 diabetes
Xue, Q., Yuan, L., Zhou, J., Li, W., Wang, H., Hong, Z., & Zhou, X. (2026) · European Journal of Integrative Medicine · doi:10.1016/j.eujim.2026.102618
Lanty, A., & Sebelski, C. A. (2026) · Journal of Women s & Pelvic Health Physical Therapy · doi:10.1097/jwh.0000000000000360
Stokes, J., Stewart, K. D., Jordan, J. B., Matza, L. S., Burgess, S., Brunt, D. V., & Hutti, J. E. (2026) · Patient Related Outcome Measures · doi:10.2147/prom.s558968
Shah, B., Kim, J., Wicker, A., Roth, J. A., Demirjian, V., & Latymer, M. (2026) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2026.2621021
“A key advancement in the assessment of disease-modifying antirheumatic drug treatment efficacy is patient-reported outcome (PRO) measures [89].”
Wang, S., Roxas, A., Saravia, B., Kim, B. K., Chowdhury, D., Riachi, N. J., Tai, M. S., Tanprawate, S., Tran, T. N., Zhao, Y. J., et al. (2026) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000200565
Teodoro, P., Fernandes, R. M., Ribeiro, I., & Ferreira-da-Silva, R. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1719963
Xu, C., Lin, Z.-Q., Wang, Y., Shen, J.-X., Li, W., Zhou, G., Yang, K., Wen, M.-Y., Zhang, Y.-N., Shen, L., et al. (2026) · Med · doi:10.1016/j.medj.2025.100994
Karvelas, N., Connor, S., Burroso, A., Coale, K., Duarte, M. L., Xiong, Y., Ncube, L., Kunney, C., Banerjee, D., Kennedy, M., et al. (2026) · Cerebral Circulation - Cognition and Behavior · doi:10.1016/j.cccb.2026.100534 · Cited by 3
Empowering Patients in Clinical Research: A Narrative Review
Sharma, P., Bagai, P., Bondia, A., Singhal, N., & Sahu, S. R. (2026) · Cureus · doi:10.7759/cureus.104763
“While conventional trials often focus on endpoints such as survival and tumor size reduction, the inclusion of PROs enables a more comprehensive evaluation of how treatments affect daily functioning, emotional well-being, and overall quality of life [27,32,33].”
Polikarpov, D. M., Yu, V., Chung, E., & Gillatt, D. A. (2026) · Trends in Urology & Men s Health · doi:10.1002/tre.70024
“Our data remains limited by the use of patient‐reported surveys and questionnaires: although these provide valuable insights into device performance and user experience in the clinical setting, they do not necessarily offer objective outcomes and are at risk of reporting bias [8].”
Sources of Data Used in Pharmacoepidemiology and Pharmacovigilance
Chinzowu, T., & Nishtala, P. S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-26472-6.00082-6
Williams, L. R., Marongiu, A., Filippidis, F. T., Heinzkill, M., van Troostenburg, A., Haubrich, R., & Ramroth, H. (2026) · PLoS ONE · doi:10.1371/journal.pone.0344968
“However, concerns have been raised over their analysis and reporting [8,9], particularly regarding the handling of high rates of missing data, the use of unsuitable methods of statistical analysis and lack of consistency of analytical approaches across studies [10,11].”
Pernice, H. F., Piazza, E., Asaad, E., Wetzel, P. J., & Hahn, K. (2026) · European Journal of Neurology · doi:10.1111/ene.70532
“…disease severity independently [37], the combination of a wide range of COMs and PROMs used in this study in an attempt to determine the “ground truth” of disease severity approximates the “true” severity, and especially respects the individuals' disease experience and daily life function [38].”
Missing data considerations for patient reported outcome measures in randomized controlled trials
Wang, F., Deng, S., Sun, J., Lin, C., Jiang, S., Norquist, J. M., Golm, G. T., Xie, J., Guan, Y., Wang, W. W. B., et al. (2026) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-026-01060-x
“Patient-Reported Outcomes (PROs) are increasingly assessed in clinical trials as primary, secondary, or exploratory endpoints, providing the patients’ perspective of treatment and the impact of medical conditions [1].”
Demidova, A., Kiknavelidze, N., Purtskhvanidze, K., Alieva, E., Ebrahimnezhad, M., Konchina, S. A., Рустамовна, Н. А., Матковський, І., Акрамовна, Э. Э., Davtian, S., et al. (2026) · Clinical & Experimental Allergy · doi:10.1111/cea.70251
Webster, K., Zola, A. R., Corona, M. E., Patten, E. A., Karmali, R., Gordon, L. I., Ma, S., Winter, J. N., Upton, A. J., Peipert, J. D., et al. (2026) · Value in Health · doi:10.1016/j.jval.2026.03.2244
Impact of comorbidity on patient reported outcome measures for men with localised prostate cancer
Parry, M. G., Bailey, A. V., Belin, T. R., Elashoff, D. A., Foster, C., Graham, I. M., Kowalski, C., Kwan, L. C., Millar, J. L., Sibert, N. T., et al. (2026) · BMC Urology · doi:10.1186/s12894-026-02146-w
“They are valuable, alongside clinician-reported data, for a more comprehensive assessment of the impact of prostate cancer treatments to inform care [6].”
Fei, S., Zhu, T., Li, S., & Zhao, H. (2026) · Journal of Cardiothoracic Surgery · doi:10.1186/s13019-026-04219-1
“In response to the limitations of traditional endpoints, a paradigm shift towards patient-centered care has high-lighted the value of incorporating Patient-Reported Outcomes (PROs) into perioperative management [4].”
A 360 Degree Qualitative Ethical Assessment of Reporting Patient Reported Outcomes
Huang, A. P., Corcoran, J., Zizzi, C. E., DeFehr, C., Contento, A., Ross, L. F., & Kluger, B. (2026) · Journal of Empirical Research on Human Research Ethics · doi:10.1177/15562646261441724
“This is particularly important because when PRO data are not the primary endpoint, they are often not returned and often not reported in publications (Kyte et al., 2014; Kyte et al., 2019; Mercieca-Bebber et al., 2018).”
Mohamed, Z. A., & Kamen, C. S. (2026) · Supportive Care in Cancer · doi:10.1007/s00520-026-10744-5 · Cited by 1
“Inconsistent implementation limited cross-validation among instruments, and underrepresentation of racially, socioeconomically, and linguistically diverse populations constrain the generalizability of findings [15, 17, 31].”
Kim, Y., Sohn, Y. J., Yoo, J. Y., Kim, M., Kim, S., & Choi, Y. J. (2026) · Healthcare · doi:10.3390/healthcare14101265
Hoang, J., Amiri, I., Dimalanta, L., Iannaccone, A., & Zhang, A. Y. (2026) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.67.5.15
“7 The ensemble of these assessments is referred to as patient-reported outcome (PRO) measures, assessments on patient perspectives rather than clinician interpretation.”
Ren, L., Liu, Y., Li, S., 岳树锦, Su, C., Wang, J., & Zhang, Y. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1770579
“In clinical practice, PROMs can enable dynamic monitoring of treatment responses and facilitate communication between clinicians and patients (14, 15).”
Epperson, M. V., Lohse, C. M., Link, M. J., & Carlson, M. L. (2026) · Otology & Neurotology · doi:10.1097/mao.0000000000004945
Sevinc, G., Escoto-Rivera, A., Crespo, K., Nesto, S., Chapman, C. A. T., & Rockwood, K. J. (2026) · Patient Related Outcome Measures · doi:10.2147/prom.s569608
“5 Building on this foundation, GAS offers distinct advantages, particularly in conditions with heterogeneous clinical profiles.”
Intelligent osteogenesis: foundations and frontiers
Galli, C., & Gruber, R. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-32950-0.00003-x
Bridging the gap: enhancing patient and public involvement in dermatology PRO research
Brookes, E., Zikos, E., Lucats, L., Notelet, L., Ferrari, G., Magnier, A., & Arnould, B. (2026) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-026-01069-2
“…the heterogeneity of patients and dermatological conditions, engagement strategies tailored to each condition not only acknowledge the unique challenges and priorities of diverse patient populations, but also aim to identify and understand the concepts that matter most to each patient group [5].”
Skingley, G., Orsini, M., Middlehurst, J., Flynn, J., Brookes, J., Blackwood, H., Clarke, N., Williams‐Hall, R., Arnould, B., Martincova, R., et al. (2026) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-026-01097-y
“This ensures that trial data meet regulatory standards (i.e., of high quality and suitable for evaluating trial outcomes) [19] and that any observed changes are an effect of treatment rather than methodological issues [43].”
Raiker, A., Raiker, A., Dean, S. M., Gasparis, A. P., & Labropoulos, N. (2026) · Journal of Vascular Surgery Venous and Lymphatic Disorders · doi:10.1016/j.jvsv.2026.102548
Kalantri, S., Kelley, B., Freeman, J. Q., Akhiwu, T. O., & Redman, R. A. (2026) · Clinical Oncology · doi:10.1016/j.clon.2026.104221
Erkol, E. E., Sevindik, O. Ş., Cömert, C., Sulhan, A., Uca, Y., Karakol, P., & Şen, E. (2026) · Journal of Plastic Reconstructive & Aesthetic Surgery · doi:10.1016/j.bjps.2026.06.010
Roy, M. K., Fort, M. P., Valdez-Vormezeele, J., Gorman, C., Pardo, J., Doan, T., Dunn, A., Messinger, A. I., Perraillon, M. C., Smyth, H. L., et al. (2026) · Contemporary Clinical Trials · doi:10.1016/j.cct.2026.108402
Expert viewpoint on endpoints in systemic sclerosis: current and future outlook
Hoffmann‐Vold, A., Distler, O., Galdo, F. D., Distler, J. H. W., Allanore, Y., Bernstein, E. J., Denton, C. P., Kuwana, M., Matucci‐Cerinic, M., Alves, M., et al. (2026) · RMD Open · doi:10.1136/rmdopen-2026-006784
“23 For SSc, PROs such as the HAQ-DI and ScleroID provide valuable insight into patient experiences related to pain, fatigue, disability and QoL, making them increasingly important in endpoint development.”
Perez, T. M., Sliwka, M., Smith-Ireland, D., Jackson, A., & Sullivan, S. G. B. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1846987
Skovfoged, M. M., Kasl, F., Koščík, M., Loutocký, P., Stupka, V., Mikulík, R., & Knoche, H. O. (2026) · ACM Conference on Conversational User Interfaces (CUI) · doi:10.1145/3816046.3816232
“…health-care systems lack comprehensive and systematic post-discharge data [104] needed to understand the long-term consequences of in-hospital care [72] and to enable proactive interventions when patients’ health deteriorates or when deterioration is likely due to non-adherence to treatment…”
van der Weijst, L., Pompili, C., Teixeira, M., Hamzeh, H., Gilbert, A., Meer, S., Piccinin, C., Salomone, F., Servetto, A., Remón, J., et al. (2026) · Lung Cancer · doi:10.1016/j.lungcan.2026.109552
Current Approaches Among Medical Providers Treating Pediatric Langerhans Cell Histiocytosis
Meyer, L. K., Abla, O., Allen, C. E., Buhtoiarov, I. N., Chow, T. T. W., Eckstein, O. S., Nk, G., Hermiston, M. L., Keenan, C., McClain, K. L., et al. (2026) · Pediatric Blood & Cancer · doi:10.1002/1545-5017.70525
Sallows, G., Sharpe, P., Henderson, P., Otieno, L. A., Ellis, D. Y., Kelly, N., Foster, M., Gabbe, B. J., Fitzgerald, M., Coombes, J., et al. (2026) · Quality of Life Research · doi:10.1007/s11136-026-04353-2
“HRQoL tools such as PROMs, are commonly used in trauma and injury (from here on referred to as injury) to capture patient perspectives on the impact of the initial injury as well as the journey to recovery through treatment and rehabilitation [2, 3 ].”
Shivarov, V. S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-30050-9.00021-7
Vosoughi, F., Oskouie, I. M., Torkamanzadeh, P., Poursalehian, M., Yazdanmehr, A., & Firoozabadi, A. A. (2026) · Journal of ISAKOS Joint Disorders & Orthopaedic Sports Medicine · doi:10.1016/j.jisako.2026.101199
Coenen, E., Almeida, D., Sepodes, B. M. N., & Torre, C. (2026) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-026-01034-7
“These approaches could fill current gaps and enable a more comprehensive evaluation of long-term treatment outcomes, ultimately strengthening the evidence base for PRO-based claims [36 ].”
Suresh, S., Parvathy, A. S., Raj, M., S., K. G., Priya, M. L., Biswas, R., Ramaiah, S., & Anbarasu, A. (2026) · Frontiers in Digital Health · doi:10.3389/fdgth.2026.1872286 · Cited by 1
“They capture patient-centered symptoms, quality of life, and functional status that are not measured by markers or lab data (49).”
Burden of fatigue in compensated chronic liver disease: findings from the multinational a:GAP StudyPreprint
Choudhuri, G., Akhundova‐Unadkat, G., Naidoo, N., Morales-Castillo, M., Guillaume, X., Duijnhoven, R. G., Safaei, A., & Swain, M. G. (2026) · medRxiv · doi:10.64898/2026.08.28.26361618
Zewdu, F. T., Alemu, K., Lambert, S. M., Misganaw, B., Abebe, Z. B., Shegaw, E. F., Nigusse, T., Ayana, G. M., Molla, E., Pullan, R. L., et al. (2026) · PLOS Global Public Health · doi:10.1371/journal.pgph.0006930
“Participants were also asked about symptom relief, changes in appearance, and overall treatment satisfaction [20].”
Wang, S., Zhang, Q., Jiang, Z., Tong, Z., Li, W., Wang, J., Ouyang, Q., Yao, T., Wang, Y., Sun, M., et al. (2026) · ESMO Open · doi:10.1016/j.esmoop.2026.108538
Barbas-Monjo, M. Á., Romero, E. A. S., Soriano, J. V., Cabrero‐García, J., Cuenca‐Zaldívar, J. N., & Sillevis, R. (2026) · International Wound Journal · doi:10.1111/iwj.71042
Subjektive data i ulik forkledning
Fauske, L., Bruland, Ø., Larsen, S. G., & Brustugun, O. T. (2026) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.26.0418
Mitchell, A. M., Paramanandam, V. S., Li, D., Donhauser, T., Waters, N. F., Hayles, C., Gower, B., Rajapakse, D., Dickens, E., Suhood, A., et al. (2026) · Patient Related Outcome Measures · doi:10.1080/1179271x.2026.2732841
Comparison of 3D-Printed Versus Analog Occlusal Splints on Patient-Reported Outcomes
Bucci, R., Michelotti, A., D’Antonio, M., Iacono, C., Vollaro, S., Nappo, P., Rongo, R., & D’Antò, V. (2026) · Applied Sciences · doi:10.3390/app16199537
Giorgino, F., Haluzík, M., Alvarez, A., Lauand, F., Assaad-Khalil, S. H., Thacker, H. P., Klupa, T., Deyneli, O., & Rosenstock, J. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71436
Chamorro-Lange, C., & Ortiz, H. A. D. L. B. (2026) · Physiotherapy Quarterly · doi:10.5114/pq/218497
“Patient-reported outcome measures (PROMs) play a central role in capturing patients’ perceptions of functional limitations and disability [7, 8].”
Rodríguez‐Hernández, A. G. (2026) · SAP Dentistry · doi:10.62486/dent2026276
Czech, E., Margariti, E., Morgan, C., Whone, A. L., Craddock, I. J., Durrant, A. C., Kirk, D., O’Kane, A. A., & O'Hara, K. (2026) · JMIR Formative Research · doi:10.2196/92174
Metadata
- Authors
- Mercieca-Bebber, R., King, M. T., Calvert, M. J., Stockler, M. R., & Friedlander, M.
- Affiliations
- The University of Sydney (AU)
- National Institute for Health and Care Research (GB)
- Corresponding author
- Friedlander, Michael
- Venue
- Patient Related Outcome Measures
- Publisher
- Informa UK Limited
- Published
- 2018-11
- Volume
- Volume 9
- Pages
- 353-367
- ISSN
- 1179-271X (ISSN-L)
- PMC
- PMC6219423
- OpenAlex
- W2899320385
- Cited by
- 659
- References
- 73
- Citations by year
- 2026: 77 · 2025: 129 · 2024: 138 · 2023: 88 · 2022: 85 · 2021: 75 · 2020: 54 · 2019: 12
- FWCI
- 4.87
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Patient Related Outcome Measures (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- University Hospitals Birmingham NHS Foundation Trust
- Australian Government
- National Institute for Health and Care Research
- University of Birmingham
- Cancer Australia
- Surgical Reconstruction and Microbiology Research Centre
- National Health and Medical Research Council
- Birmingham Biomedical Research Centre
- Topics
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Keywords
- patient-reported outcomes, clinical trial endpoints, missing data, protocol design, patient-centered outcomes, regulatory guidelines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.